🟢 LLY is trading 3% up today on positive Phase 3 data for oral drug orforglipron

LLY is trading at +3.06% now at $1073.65 following the announcement of positive Phase 3 trial results for its oral weight-loss drug, orforglipron.

• The trial demonstrated that patients maintained weight loss better than placebo after switching from injectables (such as Zepbound).
• This GLP-1 pipeline advance reinforces Eli Lilly's leadership position in the rapidly expanding obesity treatment market.
• The stock's movement aligns with today's generally upbeat market sentiment, fueled by cooler-than-expected November CPI data.